ENTX | Entera Bio Ltd. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.5373 - 1.5900
52 Week Range	0.5200 - 3.35
Beta	2.00
Implied Volatility	427.52%
IV Rank	48.55%
Day's Volume	19,373
Average Volume	64,539
Shares Outstanding	36,832,200
Market Cap	56,721,588
Sector	Healthcare
Industry	Biotechnology
IPO Date	2018-06-28

Valuation
Profitability
Growth
Health
P/E Ratio	-5.92
Forward P/E Ratio	N/A
EPS	-0.26
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	17
Country	Israel
Website	ENTX

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

ENTX's peers: NLSP, VCNX, ATHE, ENOB, IMMP, GLSI, QLGN, VTGN

*Chart delayed

Analyzing fundamentals for ENTX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is passable. For more detailed analysis please see ENTX Fundamentals page.

Watching at ENTX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on ENTX Technicals page.